Gary A Lyons is of Travere Therapeutics, Inc.. Currently has a direct ownership of 51,000 shares of TVTX, which is worth approximately $906,780. The most recent transaction as insider was on Oct 04, 2024, when has been sold 40,000 shares (Common Stock) at a price of $14.75 per share, resulting in proceeds of $590,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 51K
0% 3M change
14.61% 12M change
Total Value Held $906,780

GARY A LYONS Transaction History

Date Transaction Value Shares Traded Shares Held Form
Oct 04 2024
SELL
Open market or private sale
$590,000 $14.75 p/Share
40,000 Reduced 43.96%
51,000 Common Stock
Oct 04 2024
BUY
Exercise of conversion of derivative security
$419,200 $10.48 p/Share
40,000 Added 30.53%
91,000 Common Stock
May 08 2024
BUY
Grant, award, or other acquisition
-
6,500 Added 11.3%
51,000 Common Stock
May 17 2023
BUY
Grant, award, or other acquisition
-
4,500 Added 9.18%
44,500 Common Stock
May 11 2022
BUY
Grant, award, or other acquisition
-
3,000 Added 6.98%
40,000 Common Stock
May 14 2021
BUY
Grant, award, or other acquisition
-
3,000 Added 7.5%
37,000 Common Stock

Also insider at

HGEN
HUMANIGEN, INC Healthcare
BBI
Brickell Biotech, Inc. Healthcare
NBIX
NEUROCRINE BIOSCIENCES INC Healthcare
RIGL
RIGEL PHARMACEUTICALS INC Healthcare
ELDN
Eledon Pharmaceuticals, Inc. Healthcare
GAL

Gary A Lyons

South San Francisco, CA

Track Institutional and Insider Activities on TVTX

Follow Travere Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TVTX shares.

Notify only if

Insider Trading

Get notified when an Travere Therapeutics, Inc. insider buys or sells TVTX shares.

Notify only if

News

Receive news related to Travere Therapeutics, Inc.

Track Activities on TVTX